Pfizer (PFE) Retained Earnings (2016 - 2025)
Pfizer (PFE) has disclosed Retained Earnings for 17 consecutive years, with -$8.1 billion as the latest value for Q4 2025.
- On a quarterly basis, Retained Earnings fell 2.89% to -$8.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.1 billion, a 2.89% decrease, with the full-year FY2025 number at -$8.1 billion, down 2.89% from a year prior.
- Retained Earnings was -$8.1 billion for Q4 2025 at Pfizer, roughly flat from -$8.1 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $131.1 billion in Q2 2023 to a low of -$8.6 billion in Q1 2025.
- A 5-year average of $54.0 billion and a median of $45.8 billion in 2021 define the central range for Retained Earnings.
- Biggest YoY gain for Retained Earnings was 2484.07% in 2022; the steepest drop was 108.03% in 2022.
- Pfizer's Retained Earnings stood at $103.4 billion in 2021, then crashed by 108.03% to -$8.3 billion in 2022, then increased by 4.13% to -$8.0 billion in 2023, then increased by 1.49% to -$7.8 billion in 2024, then decreased by 2.89% to -$8.1 billion in 2025.
- Per Business Quant, the three most recent readings for PFE's Retained Earnings are -$8.1 billion (Q4 2025), -$8.1 billion (Q3 2025), and $117.6 billion (Q2 2025).